Table 1.
Patient characteristics and mutation analysis
| All patients, n = 188 (%) |
Prostate cancer Dx, n = 11 (%) |
|
|---|---|---|
| Median age (years)a | 46 (Q1;Q4 = 33;56) |
61 (Q1;Q4 = 59;71) |
| Race | ||
| Caucasian | 176 (95.1%) | 11 (100%) |
| African American | 7 (3.8%) | 0 |
| Asian | 2 (1.1%) | 0 |
| Hispanic | 0 | 0 |
| MMR gene mutation | ||
| MLH1 | 51 (27.1%) | 1 (9.1%) |
| MSH2 | 87 (46.3%) | 7 (63.6%) |
| MSH6 | 24 (12.8%) | 2 (18.2%) |
| PMS2 | 26 (13.8%) | 1 (9.1%) |
| MMR mutation type | ||
| Del/ins | 47 (25%) | 2 (18.1%) |
| Large genomic del/dup | 40 (21.3%) | 4 (36.5%) |
| Missense | 25 (13.3%) | 0 |
| Nonsense | 25 (13.3%) | 2 (18.1%) |
| At splice site | 51 (27.1%) | 3 (27.3%) |
| Location of index cancer | ||
| Colonic | 77 (41%) | 5 (45.5%) |
| Extracolonic | 26 (13.8%) | 6 (54.5%) |
| No cancer diagnosed | 85 (45.2%) | N/A |
| Mean follow-up time ± SD (years) |
6.2 ± 7.2 | 6.4 ± 4.8 |
Dx, diagnosed; MMR, mismatch repair; n, number; N/A, not applicable; Q, quartile; SD, standard deviation.
a
At MMR mutation diagnosis.